

in vitro

/ / :

Title: In vitro study of interaction of some phenothiazines and purines with famciclovir metabolism catalyzed by guinea pig liver aldehyde oxidase.

Authors: Rashidi MR.¹, Malek, A.², Hanaee J.³, Hamidi A.⁴

Abstract: Famciclovir is a guanosine nucleoside analogue with activity against herpes viruses and hepatitis B virus. Following oral administration, famciclovir is rapidly hydrolyzed to 6-deoxypenciclovir which undergoes extensive oxidation to penciclovir. *In vitro* studies have shown that both famciclovir and 6-deoxypenciclovir serve as substrates for hepatic aldehyde oxidase. Thus, it would be likely that those compounds that act as aldehyde oxidase inhibitors/substrates interfere with penciclovir formation. In the present *in vitro* study, the possible interaction of some phenothiazines and purins with the metabolism of famciclovir is investigated. Aldehyde oxidase was partially purified from guinea pig liver and the interaction of chlorpromazine, promethazine, phenothiazine, azathioprine, 6-mercaptopurine, theophylline, caffeine and allopurinol with famciclovir or 6-deoxypenciclovir oxidation was investigated using spectrophotometric or HPLC methods. Only phenothiazines caused marked inhibition on both oxidations with chlorpromazine giving the highest inhibition. The oxidation of famciclovir or 6-deoxypenciclovir was not significantly affected by allopurinol (the xanthine oxidase inhibitor) confirming that aldehyde oxidase, not xanthine oxidase, is the major molybdenum hydroxylase in the oxidation of both substrates in guinea pig liver fractions.

Key words: Aldehyde oxidase, famciclovir, penciclovir, drug interaction, phenothiazines, purines.

1-Associate Professor, Drug Applied Research Center, School of Pharmacy, Tabriz University of Medical Sciences

2- Associate Professor, School of Medicine , Tabriz University of Medical

Sciences.

3- Associate Professor, School of Pharmacy, Tabriz University of Medical

Sciences.

4- M.Sc, of Physical chemistry, School of Pharmacy, Tabriz University of Medical

Sciences.

B

in vitro

HPLC

()

Harrell .()

.()

NADPH

1

） （

%

.(

(xanthine: O₂ oxidoreductase

()

EC 1.2.3.2)

.() ()

in vitro

varicellzoster

herpes simplex

.()

(aldehyde: O₂ oxidoreductase EC 1.2.3.1)

.()
in vivo
)
(P450
(
.(.)
SmithKline)
Beecham ()
Pierce (BSA) (.)
Sigma .

Dunkin-Hartley (g)
()
KCl °C)
EDTA / mM (% / w/v, .(.)
.
.
.
.
.
UV-VIS
Shimadzu 2101 ()
μM


/ mM pH= Sorenson
() EDTA

Sorenson
EDTA / mM pH=


Vmax () Km
() K_I ()
Lineweaver-Burke plot
. () Shimadzu

Pierce BCA Protein Assay
. ()

HPLC 510 Waters
UV- WISP 710B
Spherisorb :
ODS2 5μm (25 cm x 4.6 mm, i.d.)
μBondapack C18
(pH = / / mM)
/ ml/min (:) nm
(μM) ml
/ mM (mM pH =) °C EDTA
μl % μl
/ / μl
. () HPLC
μM ()
) ()



HPLC



Lineweaver-Burk



() .()
() .()
ng/ml IC₅₀
 μM / μM
mg ng/ml mg mg
in vitro () in vivo () ()
Archive of SID
in vivo

Rererences:

- 1- Manns MP., Neuhaus P., Atkinson G.F.
Griffin K.E., Barnass S., Vollmar J., Yeang
Y., Young C.L. Famciclovir treatment of
hepatitis B infection following liver

transplantation: a long-term, multi-centre study, *Transpl Infect Dis.*, 2001, 3: 16-23.

2- Perry C.M., Wagstaff A.J. Famciclovir: a review of its pharmacological properties

-
- and therapeutic efficacy in herpesvirus infections, Drugs, 1995, 50: 396-475.
- 3- Pue M.A., Benet L.Z. Pharmacokinetics of famciclovir in man, Antiviral Chem. Chemother., 1993, 4 (Suppl. 1): 47-55.
- 4- Murray A.B. Valaciclovir: an improvement over acyclovir for the treatment of zoster, Antiviral Chem. Chemother., 1995, 6: 34-38.
- 5- Vere Hodge R.A., Perkins R.M. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells, Antimicrob Agents Chemother., 1989, 33: 223-229.
- 6- Vere Hodge R.A., Cheng Y-C. The mode of action of penciclovir. Antiviral Chem. Chemother., 1993, 4 (Suppl. 1): 13-24.
- 7- Filer C.W., Allen G.D., Brown T.A., Foeles S.E., Hollis F.J., Mort E.E., Prince W.T. Ramji J.V. Metabolic and pharmacokinetic studies following oral administration of ¹⁴C-famciclovir to healthy subjects, Xenocotica 1994, 24: 357-368.
- 8- Harrell A.W., Wheeler S.M., Pennick M., Clarke S.E., Chinery R.J. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 β -hydroxylation of testosterone in human liver microsomes, Drug Metab Dispos., 1993, 21: 18-23.
- 9- Rashidi M.R. PhD Thesis, University of Bradford, UK, 1996.
- 10- Rashidi M.R., Smith J.A., Clarke S.E., Beedham C. *In vitro* oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver, Drug Metab Dispos., 1997, 25: 805-813.
- 11- Daniels S., Schentag J.J. Drug interactions studies and safety of famciclovir in healthy volunteers: a review, Antiviral Chem. Chemother., 1993, 4 (Suppl. 1): 57-64.
- 12- Beedham C. The role of non-P450 enzymes in drug oxidation, Pharm World Sci., 1997, 19: 255-63.
- 13- Beedham C. Molybdenum hydroxylases: biological distribution and substrate inhibitor specificity. In: Progress in Medicinal Chemistry, Ellis G.P., West G.B. Eds.; Elsevier, Amsterdam, New York, Oxford, 1987, Vol. 24, pp. 85-127.
- 14- Jordan C.G., Rashidi M.R., Laljee H., Clarke S.E., Brown J.E., Beedham C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man, J Pharm Pharmacol., 1999, 51: 411-418.
- 15- Johnson C., Beedham C., Stell J.G.P. Reaction of 1-aminophthalazine and 1-chlorophthalazine with mammalian molybdenum hydroxylases *in vitro*, Xenobiotica, 1987, 17: 17-24.
- 16- Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano

- M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk C. Measurement of protein using bicinchoninic acid, *Anal Biochem.*, 1985, 150: 79-85.
- 17- Windholz M. Ed., *The Merck index*, 10th Edition, Merck & Co., INC, 1983.
- 18- Clarke S.E., Harrell A.W., Chenery R.J. Role of aldehyde oxidase in the *in vitro* conversion of famciclovir to penciclovir in human liver, *Drug Metab Dispos.*, 1995, 23: 251-254.
- 19- Johns D.G. Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates, *J Clin Invest.*, 1967, 46: 1492-1505.
- 20- Gilman A.G., Goodman L.S., Rall T.W., Murad F. Goodman and Gilman's *the Pharmacological Basis of Therapeutics*, 7th Edition, Macmillan Publishing Company, New York, 1985.
- 21- Taylor G., Houston J.B. Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography, *J Chromatogr.*, 1982, 230: 194-198.
- 22- Grahame-Smith D.G., Aronson J.K. *Oxford Textbook of Clinical Pharmacology and Drug Therapy*, Oxford University Press, 1991.
- 23- Yoshihara S., Tatsumi K. Kinetic and inhibition studies on reduction of diphenyl sulfoxide by guinea pig liver aldehyde oxidase, *Arch. Biochem. Biophys.*, 1986, 249: 8-14.
- 24- Moriwaki Y., Yamamoto T., Nasako Y., Takahashi S., Suda M., Hiroishi K., Hada T., Higashino K. *In vitro* oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase, *Biochem Pharmacol.*, 1993, 46: 975-981.